The importance of the eicosanoid pathway in lung cancer.
Non-steroidal anti-inflammatory agents (NSAIDs) inhibit the conversion of arachadonic acid to a class of inflammatory mediators known as eicosanoids. These minimally toxic drugs have demonstrated important anti-cancer properties in colorectal cancer and pre-clinical models have shown their potential for use in the treatment of non-small cell lung cancer (NSCLC). Clinical trials are underway investigating the efficacy of eicosanoid inhibitors alone and in combination with radiation and chemotherapy.
Laskin
Janessa J
JJ
Department of Medical Oncology and Hematology, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, 777 PRB, Nashville, TN 37215-6307, USA.
Sandler
Alan B
AB
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000378:metabolism / Q000494:pharmacology*; D000970:Antineoplastic Agents / Q000494:pharmacology*; D003131:Combined Modality Therapy; D016861:Cyclooxygenase Inhibitors / Q000494:pharmacology*; D015777:Eicosanoids / Q000037:antagonists & inhibitors* / Q000494:pharmacology*; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000503:physiopathology
D000894:Anti-Inflammatory Agents, Non-Steroidal; D000970:Antineoplastic Agents; D016861:Cyclooxygenase Inhibitors; D015777:Eicosanoids